Alexis N. Pulliam

Near-Infrared Imaging of Glymphatic Clearance in a Pre-Clinical Model of Repetitive Closed Head Traumatic Brain Injury

Eleftheria Michalaki, Alexis N. Pulliam, Pooja M. Datta Roy, J. Brandon Dixon et autres

Traumatic brain injury (TBI) is a major health disorder for which there are few treatments. The glymphatic system is the brain's inbuilt lymphatic-like system that is thought to be responsible for clearing waste products from the brain to the lymph nodes. Although …

us (code pays fourni par la source)

Spatial lipidomics maps brain alterations associated with mild traumatic brain injury

Dmitry Leontyev, Alexis N. Pulliam, Xin Ma, David A. Gaul et autres

Traumatic brain injury (TBI) is a global public health problem with 50-60 million incidents per year, most of which are considered mild (mTBI) and many of these repetitive (rmTBI). Despite their massive implications, the pathologies of mTBI and rmTBI are not fully …

us (code pays fourni par la source)

Integrative Analysis of Cytokine and Lipidomics Datasets Following Mild Traumatic Brain Injury in Rats

Alexis N. Pulliam, Alyssa F. Pybus, David A. Gaul, Samuel G. Moore et autres

Traumatic brain injury (TBI) is a significant source of disability in the United States and around the world and may lead to long-lasting cognitive deficits and a decreased quality of life for patients across injury severities. Following the primary injury phase, TBI …

us (code pays fourni par la source)

Spatial Lipidomics Maps Brain Alterations Associated with Mild Traumatic Brain Injury

Dmitry Leontyev, Alexis N. Pulliam, Xin Ma, David A. Gaul et autres

Traumatic brain injury (TBI) is a global public health problem with 50-60 million incidents per year, most of which are considered mild (mTBI) and many of these repetitive (rmTBI). Despite their massive implications, the pathologies of mTBI and rmTBI are not fully …

us (code pays fourni par la source)

Comparing Brain and Blood Lipidome Changes following Single and Repetitive Mild Traumatic Brain Injury in Rats

Alexis N. Pulliam, Eric C. Gier, David A. Gaul, Samuel G. Moore et autres

High Resolution Image Download MS PowerPoint Slide Traumatic brain injury (TBI) is a major health concern in the United States and globally, contributing to disability and long-term neurological problems. Lipid dysregulation after TBI is underexplored, and a better understanding of lipid turnover …

us (code pays fourni par la source)

Lipidome Alterations following Mild Traumatic Brain Injury in the Rat

Eric C. Gier, Alexis N. Pulliam, David A. Gaul, Samuel G. Moore et autres

Traumatic brain injury (TBI) poses a major health challenge, with tens of millions of new cases reported globally every year. Brain damage resulting from TBI can vary significantly due to factors including injury severity, injury mechanism and exposure to repeated injury events. …

us (code pays fourni par la source)

Effects of Raloxifene and tibial loading on bone mass and mechanics in male and female mice

Alycia G. Berman, John George Damrath, Jennifer M. Hatch, Alexis N. Pulliam et autres

Purpose: Raloxifene (RAL) is a selective estrogen receptor modulator (SERM) that has previously been shown to cause acellular benefits to bone tissue. Due to these improvements, RAL was combined with targeted tibial loading to assess if RAL treatment during periods of active …

us (code pays fourni par la source)

6′-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding

Katherine M. Powell, Alexa P. Brown, Cayla Skaggs, Alexis N. Pulliam et autres

Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal estrogen therapy promotes unintended side effects, such as hot flashes and increased …

us (code pays fourni par la source)

6'-Methoxy Raloxifene-analog enhances mouse bone properties with reduced estrogen receptor binding

Katherine M. Powell, Alexa P. Brown, Cayla Skaggs, Alexis N. Pulliam et autres

Raloxifene (RAL) is an FDA-approved drug used to treat osteoporosis in postmenopausal women. RAL suppresses bone loss primarily through its role as a selective estrogen receptor modulator (SERM). This hormonal estrogen therapy promotes unintended side effects, such as hot flashes and increased …

us (code pays fourni par la source)

Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone

Katherine M. Powell, Cayla Skaggs, Alexis N. Pulliam, Alycia G. Berman et autres

Abstract Current interventions to reduce skeletal fragility are insufficient at enhancing both the quantity and quality of bone when attempting to improve overall mechanical integrity. Bisphosphonates, such as Zoledronate (ZOL), are used to treat a variety of bone disorders by increasing bone …

us (code pays fourni par la source)

Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone

Katherine M. Powell, Cayla Skaggs, Alexis N. Pulliam, Alycia G. Berman et autres

us (code pays fourni par la source)